SLC5A2 and hydrops fetalis: Accordingly, both the updated consensus report (9) from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) and the guidelines (10) from the European Society of Cardiology (ESC) propose that SGLT2 inhibitors should be used for prevention of cardiorenal adverse endpoints in T2DM patients with HF or CKD or in those at high cardiorenal risk (11).